In an informal interview, new Boston Scientific CEO Mike Mahoney recounts his controversial decision to leave Johnson & Johnson and his transition into Boston Scientific, from interactions with the Board to the opinions of his kids. As for his first six months in office, recent articles suggest the company has entered a new era in its performance.
